CPRX - Catalyst Pharmaceuticals stock sinks on proposed public offering of common stock
2024-01-04 16:56:43 ET
More on Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2023 Earnings Call Transcript
- Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity
- Catalyst Pharmaceuticals appoints Kalb as its CFO
- Catalyst Pharmaceuticals Non-GAAP EPS of $0.49 beats by $0.48, revenue of $102.7M beats by $2.33M
- Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals
For further details see:
Catalyst Pharmaceuticals stock sinks on proposed public offering of common stock